Steris Plc Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by STERIS Plc on May 7, 2026, covering events occurring on May 1, 2026, and May 5, 2026. The filing addresses changes to the composition of the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to director compensation: a prorated fee of $76,989 for the new director, payable in career restricted stock units.
Material Changes
- Director Departure: Richard C. Breeden notified the Company on May 1, 2026, that he will not stand for reelection at the 2026 Annual General Meeting. His retirement follows 18 years of service and is not due to any disagreement with the Company.
- Director Appointment: On May 5, 2026, the Board increased its size from nine to ten members and appointed Pierre Boulud as a director effective immediately.
- New Director Background: Mr. Boulud, age 54, is the CEO of bioMérieux (since June 2023). His prior experience includes roles at Ipsen, Boston Consulting Group, and Bossard Consultants.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of risks and contingencies. It notes that the press release regarding the appointment is furnished under Regulation FD and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Confirm the effective date of Pierre Boulud's directorship (May 5, 2026).
- Verify the total number of Board seats following the expansion to ten members.
- Review the specific terms of the Non-Employee Director Compensation Program regarding the restricted stock units awarded to Mr. Boulud.
- Check the Company's proxy statement for the 2026 Annual General Meeting to confirm the slate of nominees following Mr. Breeden's departure.